In early 2015, we realized that there was a wealth of medical knowledge online but no intelligent interpretation or curation of it. We aimed to solve this by creating an Artificial Intelligence engine that could bring a patient to diagnosis based on their current medical state, symptoms and past medical history. In our pursuit we analyzed over 3 million patient records in engineering an AI model that could lead a naive patient right to diagnosis through simple questioning.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

STUDY PROVIDES INSIGHTS INTO HOW ALGAE SIPHON CARBON DIOXIDE FROM THE AIR

Phys | September 21, 2017

news image

Two new studies of green algae—the scourge of swimming pool owners and freshwater ponds—have revealed new insights into how these organisms siphon carbon dioxide from the air for use in photosynthesis, a key factor in their ability to grow so quickly. Understanding this process may someday help researchers improve the growth rate of crops such as wheat and rice....

Read More

INCYTE HAS INSIGHT INTO MARKET WITH POTENTIAL BLOCKBUSTER DRUGS

biotech | January 23, 2017

news image

The biotech industry has a mixed outlook for 2017 with few new drugs coming to market this year, but midcap Incyte (INCY) is one of the few companies with potential blockbusters in its pipeline.Incyte closed out 2016 and started 2017 with some major developments. The first came late last year when the company discovered that its Jakafi drug won't be facing competition from Gilead(GILD) in 2018 as previously expected. Jakafi is used to treat two maladies: myelofibrosis, a bone marrow di...

Read More

AFTER CLOSING ONE OF CHINA'S BIGGEST-EVER RAISES, I-MAB BIOPHARMA NABS $104M NASDAQ IPO

FierceBiotech | January 17, 2020

news image

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite. It hit $14 a share, the midpoint in the range, and becomes the first Chinese biotech in more than two years (the last being Zai Lab back in 2017) to gain a U.S. IPO. According to recent reports out of Bloomberg, however, it had been quietly hoping for a $200 million offering. The offering seems relatively tame after the monster raises it has gained over the years, including $22...

Read More

STEM CELL MODELS OF HUMAN SPINE DEVELOPMENT UNVEILED

Drug Target Review | January 15, 2020

news image

Scientists have created the first lab-dish models of the cellular clock, where each ‘tick’ stimulates the formation of the vertebra, which uses stem cells derived from adult human tissue. Over 20 years ago, Olivier Pourquié’s lab at Harvard University, US discovered a cellular clock in chicken embryos where each ‘tick’ stimulates the formation of a structure called a somite that ultimately becomes a vertebra. Now, Pourquié has led one of two teams to c...

Read More
news image

STUDY PROVIDES INSIGHTS INTO HOW ALGAE SIPHON CARBON DIOXIDE FROM THE AIR

Phys | September 21, 2017

Two new studies of green algae—the scourge of swimming pool owners and freshwater ponds—have revealed new insights into how these organisms siphon carbon dioxide from the air for use in photosynthesis, a key factor in their ability to grow so quickly. Understanding this process may someday help researchers improve the growth rate of crops such as wheat and rice....

Read More
news image

INCYTE HAS INSIGHT INTO MARKET WITH POTENTIAL BLOCKBUSTER DRUGS

biotech | January 23, 2017

The biotech industry has a mixed outlook for 2017 with few new drugs coming to market this year, but midcap Incyte (INCY) is one of the few companies with potential blockbusters in its pipeline.Incyte closed out 2016 and started 2017 with some major developments. The first came late last year when the company discovered that its Jakafi drug won't be facing competition from Gilead(GILD) in 2018 as previously expected. Jakafi is used to treat two maladies: myelofibrosis, a bone marrow di...

Read More
news image

AFTER CLOSING ONE OF CHINA'S BIGGEST-EVER RAISES, I-MAB BIOPHARMA NABS $104M NASDAQ IPO

FierceBiotech | January 17, 2020

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite. It hit $14 a share, the midpoint in the range, and becomes the first Chinese biotech in more than two years (the last being Zai Lab back in 2017) to gain a U.S. IPO. According to recent reports out of Bloomberg, however, it had been quietly hoping for a $200 million offering. The offering seems relatively tame after the monster raises it has gained over the years, including $22...

Read More
news image

STEM CELL MODELS OF HUMAN SPINE DEVELOPMENT UNVEILED

Drug Target Review | January 15, 2020

Scientists have created the first lab-dish models of the cellular clock, where each ‘tick’ stimulates the formation of the vertebra, which uses stem cells derived from adult human tissue. Over 20 years ago, Olivier Pourquié’s lab at Harvard University, US discovered a cellular clock in chicken embryos where each ‘tick’ stimulates the formation of a structure called a somite that ultimately becomes a vertebra. Now, Pourquié has led one of two teams to c...

Read More